In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to ...

Rusfertide significantly improves hematocrit control and reduces the mean number of phlebotomies in patients who are phlebotomy-dependent despite standard care. The Food and Drug Administration (FDA) ...

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily ...

The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...

In February of 2017, Anna — who had been experiencing blinding headaches — collapsed while snooping around Wyndemere. A very worried Valentin (James Patrick Stuart) scooped her up in his arms and ...

NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. But the tide may finally be ...

The archaic practice of removing blood from the body to treat a wide range of illnesses lives on today as a standard treatment for certain blood disorders. The modern version of this approach, called ...

DEAR DR. ROACH: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his ...